Franziska Maria Ippen1,2, Julia Katharina Grosch1,2, Megha Subramanian3, Benjamin Macfarlane Kuter1, Bianca M Liederer3, Emile G Plise3, Joana Liliana Mora1, Naema Nayyar1, Stephen Paul Schmidt4, Anita Giobbie-Hurder5, Maria Martinez-Lage6, Scott L Carter7, Daniel P Cahill8, Hiroaki Wakimoto8, Priscilla Kaliopi Brastianos1. 1. Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany. 3. Genentech, Inc, Drug Metabolism and Pharmacokinetics, South San Francisco, California, USA. 4. Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 5. Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 6. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 7. Joint Center for Cancer Precision Medicine, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 8. Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43-70% of breast cancer brain metastasis patients. To date, the treatment of these patients presents an ongoing challenge, mainly because of the lack of targeted agents that are able to sufficiently penetrate the blood-brain barrier. GDC-0068 is a pan-Akt inhibitor that has shown to be effective in various preclinical tumor models as well as in clinical trials. The purpose of this study was to analyze the efficacy of GDC-0068 in a breast cancer brain metastases model. METHODS: In in vitro studies, antitumor activity of GDC-0068 was assessed in breast cancer cells of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutant and PIK3CA-wildtype breast cancer cell lines using cell viability and apoptosis assays, cell cycle analysis, and western blots. In vivo, the efficacy of GDC-0068 was analyzed in a PIK3CA-mutant breast cancer brain metastasis orthotopic xenograft mouse model and evaluated by repeated bioluminescent imaging and immunohistochemistry. RESULTS: GDC-0068 decreased cell viability, induced apoptosis, and inhibited phosphorylation of proline rich Akt substrate 40 kDa and p70 S6 kinase in a dose-dependent manner in PIK3CA-mutant breast cancer brain metastatic cell lines compared with PIK3CA-wildtype cell lines. In vivo, treatment with GDC-0068 notably inhibited the growth of PIK3CA-mutant tumors and resulted in a significant survival benefit compared with sham, whereas no effect was detected in a PIK3CA-wildtype model. CONCLUSIONS: This study suggests that the Akt inhibitor GDC-0068 may be an encouraging targeted treatment strategy for breast cancer brain metastasis patients with activating mutations in the PI3K pathway. These data provide a rationale to further evaluate the efficacy of GDC-0068 in patients with brain metastases.
BACKGROUND: Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43-70% of breast cancer brain metastasispatients. To date, the treatment of these patients presents an ongoing challenge, mainly because of the lack of targeted agents that are able to sufficiently penetrate the blood-brain barrier. GDC-0068 is a pan-Akt inhibitor that has shown to be effective in various preclinical tumor models as well as in clinical trials. The purpose of this study was to analyze the efficacy of GDC-0068 in a breast cancer brain metastases model. METHODS: In in vitro studies, antitumor activity of GDC-0068 was assessed in breast cancer cells of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutant and PIK3CA-wildtype breast cancer cell lines using cell viability and apoptosis assays, cell cycle analysis, and western blots. In vivo, the efficacy of GDC-0068 was analyzed in a PIK3CA-mutant breast cancer brain metastasis orthotopic xenograft mouse model and evaluated by repeated bioluminescent imaging and immunohistochemistry. RESULTS:GDC-0068 decreased cell viability, induced apoptosis, and inhibited phosphorylation of proline rich Akt substrate 40 kDa and p70 S6 kinase in a dose-dependent manner in PIK3CA-mutant breast cancer brain metastatic cell lines compared with PIK3CA-wildtype cell lines. In vivo, treatment with GDC-0068 notably inhibited the growth of PIK3CA-mutant tumors and resulted in a significant survival benefit compared with sham, whereas no effect was detected in a PIK3CA-wildtype model. CONCLUSIONS: This study suggests that the Akt inhibitor GDC-0068 may be an encouraging targeted treatment strategy for breast cancer brain metastasispatients with activating mutations in the PI3K pathway. These data provide a rationale to further evaluate the efficacy of GDC-0068 in patients with brain metastases.
Authors: Franziska M Ippen; Christopher A Alvarez-Breckenridge; Benjamin M Kuter; Alexandria L Fink; Ivanna V Bihun; Matthew Lastrapes; Tristan Penson; Stephen P Schmidt; Gregory R Wojtkiewicz; Jianfang Ning; Megha Subramanian; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla K Brastianos Journal: Clin Cancer Res Date: 2019-02-22 Impact factor: 12.531
Authors: Leni S Jacob; Sakari Vanharanta; Anna C Obenauf; Mono Pirun; Agnes Viale; Nicholas D Socci; Joan Massagué Journal: Cancer Res Date: 2015-07-24 Impact factor: 12.701
Authors: Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis Journal: Cancer Discov Date: 2015-09-26 Impact factor: 39.397
Authors: Barbara Adamo; Allison M Deal; Emily Burrows; Joseph Geradts; Erika Hamilton; Kimberly L Blackwell; Chad Livasy; Karen Fritchie; Aleix Prat; J Chuck Harrell; Matthew G Ewend; Lisa A Carey; C Ryan Miller; Carey K Anders Journal: Breast Cancer Res Date: 2011-12-01 Impact factor: 6.466
Authors: Megan R D'Andrea; Corey M Gill; Melissa Umphlett; Nadejda M Tsankova; Mary Fowkes; Joshua B Bederson; Priscilla K Brastianos; Raj K Shrivastava Journal: Oncologist Date: 2019-11-06
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Cedric Tehranian; Laura Fankhauser; Patrick N Harter; Colin D H Ratcliffe; Pia S Zeiner; Julia M Messmer; Dirk C Hoffmann; Katharina Frey; Dana Westphal; Michael W Ronellenfitsch; Erik Sahai; Wolfgang Wick; Matthia A Karreman; Frank Winkler Journal: Neuro Oncol Date: 2022-02-01 Impact factor: 12.300
Authors: E S Bergen; P Scherleitner; P Ferreira; B Kiesel; C Müller; G Widhalm; K Dieckmann; G Prager; M Preusser; A S Berghoff Journal: ESMO Open Date: 2021-06-04